Last Price$2.61Cboe Real-Time Last Sale as of 11:03AM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.06(2.16%)
Bid (Size)$2.60 (1,290)
Ask (Size)$2.61 (1,400)
Day Low / High$2.57 - 2.65
Volume475.3 K

VBI Vaccines, Agenus to Collaborate on Phase 2 Trial of Brain Cancer Combination Therapy Candidate

10:19AM ET 10/12/2022 MT Newswires
VBI Vaccines (VBIV) and Agenus (AGEN) said Wednesday they are collaborating on a phase 2 trial of a potential combination therapy for primary glioblastoma, a type of brain cancer.

The collaboration seeks to evaluate the combination of VBI's cancer vaccine immunotherapeutic candidate, VBI-1901, and Agenus' monoclonal antibody, balstilimab, in patients who had tumor removal and radiotherapy, the companies said.

VBI-1901 is currently in a mid-stage study, where it showed "encouraging" tumor responses and improvement in overall survival compared with historical controls, the companies said.

Under the terms of the collaboration, VBI will sponsor the study and will be responsible for the execution of the trial, while Agenus will supply balstilimab.

Financial terms of the collaboration were not disclosed.

VBI Vaccines shares rose 3.8% in recent trading, while Agenus shares plummeted 9.2%.

Price: 0.67, Change: +0.02, Percent Change: +3.78